Literature DB >> 25318976

Diagnosis and management of non-criteria obstetric antiphospholipid syndrome.

Deepa R Jayakody Arachchillage1, Samuel J Machin, Ian J Mackie, Hannah Cohen.   

Abstract

Accurate diagnosis of obstetric antiphospholipid syndrome (APS) is a prerequisite for optimal clinical management. The international consensus (revised Sapporo) criteria for obstetric APS do not include low positive anticardiolipin (aCL) and anti β2 glycoprotein I (aβ2GPI) antibodies (< 99th centile) and/or certain clinical criteria such as two unexplained miscarriages, three non-consecutive miscarriages, late pre-eclampsia, placental abruption, late premature birth, or two or more unexplained in vitro fertilisation failures. In this review we examine the available evidence to address the question of whether patients who exhibit non-criteria clinical and/or laboratory manifestations should be included within the spectrum of obstetric APS. Prospective and retrospective cohort studies of women with pregnancy morbidity, particularly recurrent pregnancy loss, suggest that elimination of aCL and/or IgM aβ2GPI, or low positive positive aCL or aβ2GPI from APS laboratory diagnostic criteria may result in missing the diagnosis in a sizeable number of women who could be regarded to have obstetric APS. Such prospective and retrospective studies also suggest that women with non-criteria obstetric APS may benefit from standard treatment for obstetric APS with low-molecular-weight heparin plus low-dose aspirin, with good pregnancy outcomes. Thus, non-criteria manifestations of obstetric APS may be clinically relevant, and merit investigation of therapeutic approaches. Women with obstetric APS appear to be at a higher risk than other women of pre-eclampsia, placenta-mediated complications and neonatal mortality, and also at increased long-term risk of thrombotic events. The applicability of these observations to outcomes in women with non-criteria obstetric APS remains to be determined.

Entities:  

Keywords:  Antiphospholipid syndrome; aspirin; heparin; international consensus criteria; low titre aPL; obstetric APS; recurrent miscarriages

Mesh:

Substances:

Year:  2014        PMID: 25318976     DOI: 10.1160/TH14-05-0416

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

Review 1.  Diagnosis and management of the antiphospholipid syndrome.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Blood Rev       Date:  2017-07-30       Impact factor: 8.250

Review 2.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

3.  Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy.

Authors:  Eleftheria Lefkou; Apostolos Mamopoulos; Themistoklis Dagklis; Christos Vosnakis; David Rousso; Guillermina Girardi
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

Review 4.  Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic Concepts.

Authors:  Roger A Levy; Flavia Cunha Dos Santos; Guilherme R de Jesús; Nilson R de Jesús
Journal:  Front Immunol       Date:  2015-05-07       Impact factor: 7.561

Review 5.  Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions.

Authors:  Asher Bashiri; Katherine Ida Halper; Raoul Orvieto
Journal:  Reprod Biol Endocrinol       Date:  2018-12-05       Impact factor: 5.211

Review 6.  Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis.

Authors:  Maria Letizia Urban; Alessandra Bettiol; Irene Mattioli; Alfredo Vannacci; Elena Silvestri; Domenico Prisco; Giacomo Emmi; Gerardo Di Scala; Laura Avagliano; Niccolò Lombardi; Giada Crescioli; Gianni Virgili; Caterina Serena; Federico Mecacci; Claudia Ravaldi
Journal:  Intern Emerg Med       Date:  2021-01-21       Impact factor: 3.397

7.  Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome.

Authors:  Katrien M J Devreese; Stéphane Zuily; Pier Luigi Meroni
Journal:  J Transl Autoimmun       Date:  2021-11-06

8.  Recurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050).

Authors:  Bettina Toth; Wolfgang Würfel; Michael Bohlmann; Johannes Zschocke; Sabine Rudnik-Schöneborn; Frank Nawroth; Ekkehard Schleußner; Nina Rogenhofer; Tewes Wischmann; Michael von Wolff; Katharina Hancke; Sören von Otte; Ruben Kuon; Katharina Feil; Clemens Tempfer
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-04-27       Impact factor: 2.915

9.  Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report.

Authors:  Yogesh Sharma; Karen Humphreys; Campbell Thompson
Journal:  J Med Case Rep       Date:  2018-08-14

10.  Immunomodulatory Effects of Vitamin D in Pregnancy and Beyond.

Authors:  Farhan Cyprian; Eleftheria Lefkou; Katerina Varoudi; Guillermina Girardi
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.